Press Releases Valneva

Equities

VLA

FR0004056851

Market Closed - Euronext Paris Other stock markets 09:07:18 29/04/2024 pm IST			After market 01:04:32 am
3.466 ^EUR	+0.64%		3.414	-1.50%

11/04	Valneva: Deep Track Biotechnology Master holds less than 5% of the capital	CF
26/03	Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valneva : Document AMF CP. 2024E960493	16/04	PU
World Vaccine Congress Washington: Antibody persistence of a single-dose live-attenuated chikungunya virus vaccine in adults	04/04	PU
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	26/03	AQ
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	26/03	GL
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F	25/03	GL
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F	25/03	AQ
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook	21/03	AQ
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.	21/03	GL
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook	20/03	GL
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook	20/03	AQ
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed	18/03	GL
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences	04/03	GL
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences	04/03	AQ
U.S. CDC Advisory Committee Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ	01/03	AQ
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®	29/02	GL
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance	15/02	GL
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance	15/02	AQ
Valneva Announces Sale of Priority Review Voucher for $103 Million	05/02	GL
Valneva Announces Sale of Priority Review Voucher for $103 Million	05/02	AQ
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine	10/01	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Valneva

Equities

VLA

FR0004056851

Press Releases

Filters